Trial Profile
MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2020 Status changed from active, no longer recruiting to completed.
- 01 May 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2017 Early results (n=44) assessing safety and efficacy presented at the 59th Annual Meeting and Exposition of the American Society of Hematology